Published in Cancer Weekly, July 2nd, 2002
The data were reported at the American Society of Clinical Oncology annual meeting. Tumor responses were demonstrated in 90% of patients who entered the trial with measurable disease in the radiation field. Also, no clinically significant side effects over what was anticipated from the radiation therapy were reported.
Dr. Ed Gubish, EntreMed president and chief operating officer said, "With these phase I results, we will move Angiostatin forward...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.